No Major Damage for Japanese Pharmaceutical Industry

13 March 2011 (Last Updated March 13th, 2011 18:30)

Preliminary reports suggest that no major damage to pharmaceutical facilities in Japan has been sustained in the wake of last week's earthquake and tsunami. Danish pharmaceutical company Novo Nordisk will assess its supply operations, but confirmed its plant had remained undamaged.

Preliminary reports suggest that no major damage to pharmaceutical facilities in Japan has been sustained in the wake of last week's earthquake and tsunami.

Danish pharmaceutical company Novo Nordisk will assess its supply operations, but confirmed its plant had remained undamaged.

The factory is located in Koriyama, some 60km away from the Fukushima nuclear power plant that suffered explosions, but most of the company’s staff are located in Tokyo. All of its employees in the country have been accounted for.

Japanese pharma major Takeda Pharmaceutical is still assessing the impact of the disaster, but also confirmed that its facilities in Tokyo, Osaka and Hikari had not appeared to suffer any major damage.

Merck confirmed that its employees in Tokyo, Shiga and Menuma are safe and the company expects to resume normal operation on Monday, and US-based Johnson & Johnson has accounted for most of its employees in the country.

Eisai reported some damage to its Tokyo-area facilities.